News Releases

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre Limited (RCUK SSC Ltd). RCUK SSC Ltd has been set up by the seven Research Councils of the UK (RCUK) to provide centralized services to the Research Councils and their institutes in various areas including procurement.

Combination of Technologies Set to Increase Success Rates in Drug Development

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec has signed a license agreement with VU University Medical Center (VUmc), which provides AbD Serotec with worldwide exclusive rights to commercialize a number of antibody clones for research applications. These include the world’s most widely used reagents for studying macrophage subsets in rats, the “ED series” of antibodies.